Pathogenesis and therapy of interstitial nephritis  by Neilson, Eric G.
Kidney International, Vol. 35 (1989), PP. 1257—1270
NEPHROLOGY FORUM
Pathogenesis and therapy of interstitial nephritis
Principal discussant: ERIC G. NEILs0N
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
An otherwise healthy, 27-year-old white female went to her local
physician complaining of 2 weeks of fever, malaise, and poor appetite.
She was taking no medication and had no history of substance abuse.
Physical examination revealed pallor and a temperature of 101°F
orally; the blood pressure was 110/70 mm Hg. Her eye grounds were
normal, no lymphadenopathy was present, the chest was clear to
auscultation and percussion, and she had no extra heart sounds. An
abdominal examination was within normal limits, pelvic examination
revealed no adnexal masses or tenderness, and a general neurologic
examination was within normal limits. Urinalysis revealed a pH of 5.5,
with +1 protein, a trace of blood, and no glucose. Microscopic
examination revealed 10 to 12 white blood cells/high-powered field, 10
to 15 red blood cells/high-powered field, occasional epithelial cells, and
2 white blood cell casts; a stain for eosinophils was negative. Routine
screening tests revealed a hemoglobin of 11.4 g/dl; the white blood cell
count was 11,500 mm3, with 85% polymorphonuclear leukocytes, 5%
bands, 1% eosinophils, and 9% monocytes. Sodium was 134 mEq/liter;
potassium, 4.8 mEq/liter; bicarbonate, 25 mEq/liter; and chloride, 103
mEq/liter. The BUN was 34 mg/dl, and the creatinine was 2.1 mg/dl.
Glucose was 114 mg/dl. A 24-hour urine collection revealed 1 g of
creatinine, 800 mg of protein, and a creatinine clearance of 33 mI/mm.
A plain chest film was normal, and serologic studies were unrevealing.
The patient was admitted to the hospital, where a renal biopsy was
performed subsequent to a diagnostic ultrasound examination, blood
cultures, and a urine culture, The cultures were negative and the renal
sonogram demonstrated two kidneys approximately 13.5 cm in length
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without evidence of obstruction. The renal biopsy revealed 20 glomer-
uli, all appearing normal, which were surrounded by an active mono-
nuclear infiltrate; tubular destruction and early fibrogenesis, principally
confined to diffuse areas of the cortex, were present. Immunofluores-
cent examination of the biopsy specimen also demonstrated linear
staining of the proximal tubules by IgG and C3 extending into Bow-
man's capsule. The patient was treated with a course of immunosup-
pression.
Discussion
DR. ERIC G. NEILSON (Chief, Renal Electrolyte Section,
Hospital of the University of Pennsylvania, and Associate
Professor of Medicine, University of Pennsylvania School of
Medicine, Philadelphia, Pennsylvania): This young woman has
acute interstitial nephritis. Perhaps the most famous case of
interstitial nephritis was Admiral John Paul Jones, who died in
1792 with severe renal failure and hypertension [11. His autopsy
revealed advanced interstitial nephritis, presumably from lead-
contaminated water consumed aboard ship. An abbreviated
history describing our understanding of the interstitial lesion is
outlined in Table 1. Since the advent of the percutaneous renal
biopsy, this lesion has been recognized with increasing fre-
quency.
Interstitial nephritis often occurs as a primary process and
accounts for approximately 15% of the lesions in acute renal
failure [2], and up to 25% of the lesions in chronic renal failure
[3]. Interstitial nephritis also can develop as a secondary
process following glomerular or vascular injury. Interstitial
nephritis, therefore, is a final common pathway to all forms of
end-stage renal disease and is the most common and pivotal
lesion in nephrology. The importance of this form of injury is
partially underscored by a previously unrecognized literature
on structure-function relationships associated with interstitial
damage. Various morphometric correlations strongly suggest
that changes in tubular function and glomerular filtration corre-
late more strongly with the presence of progressive deteriora-
tion in interstitial architecture than with changes in glomerular
tuft integrity (Fig. 1) [4—6].
It is not obvious why interstitial damage should impede
glomerular filtration, but several theories have been advanced
to explain this structure-function correlation: the "clogged
drain," capillary bed, and vascular tone hypotheses. The first,
and most obvious, explanation is that filtrate produced by an
anatomically intact glomerular tuft cannot pass into a collecting
system through tubules that are structurally dismantled by
inflammatory infiltrates, thus the name "clogged drain." Sec-
ond is the hypothesis suggesting that a progressive decrease in
tubular vascular surface area, during the course of interstitial
nephritis, leads to an increase in resistance in the postglomeru-
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Fig. 1. Structure-function relationships. Panels A and B are from two publications [5, 6], which address structural and morphometric changes in
renal biopsies of patients with glomerular or interstitial disease. In panel A, grading scale evaluations of patient biopsies are correlated with inulin
clearance (• acute glomerulonephritis; 0 chronic glomerulonephritis; • interstitial nephritis; • nephrosclerosis; miscellaneous); y = 92—O.02X
for glomerular disease and y = 122—8.8X for interstitial disease. In panel B, comparisons also are made between biopsies graded for degrees of
normal architecture (glomerular index and tubular atrophy scores) plotted against creatinine clearance. The findings in these two studies indicate
that falling glomerular filtration correlates better with progressive intersitial changes than with changes in the glomerular tuft.
lar vascular bed. This effect would restrict outflow from the
glomeruli by reducing circulatory capacity, and filtration would
decrease [4, 7, 81. The third theory posits that, with moderate
interstitial inflammation and tubular atrophy, too little sodium is
pumped out of the proximal tubule and thick ascending limb,
and an interstitial osmotic gradient does not develop ade-
quately. Too little water, therefore, is removed from the tubular
fluid, polyuria ensues, and the increased tubular flow rate
reduces renin release from the juxtaglomerular apparatus. An-
giotensin II content concordantly decreases in the vas efferens.
The tone of the vas efferens is subsequently relaxed, and the
glomerular filtration rate falls. This effect is referred to as a
modified Thurau mechanism, whereby glomerular filtration
adapts to insufficient tubular function [4, 9].
Patho genesis
Interstitial lesions in humans fall into three distinct patterns
on renal biopsy, all of which have experimental counterparts in
mice (Table 2). The most common lesion is a mononuclear cell
infiltrate, usually in the cortical interstitium. These inflamma-
tory cells are a mixture of lymphocytes, macrophages, and
occasional plasma cells. Most of the lymphocytes are T-cells.
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Table 1. Brief history of interstitial nephritis
1792
—Admiral Jones' autopsy specimen
1800s —Autopsy lesions of interstitial injury referred to as
productive nephritis, granulating nephritis,
pyelonephntis, and lymphomatous nephritis
1898 —Councilman's description of acute interstitial nephritis
1914 —Volhard and Fahr include interstitial lesions in their
classification of renal disease
1946 —More et al describe interstitial lesions from pharmaceutical
drugs
1953
—Spuhler and Zollinger describe analgesic nephropathy
1954 —Kark and Muehrcke report on the use of percutaneous
renal biopsy
1958 —Danilovic describes interstitial disease from heavy-metal-
contaminated flour
1971—74-—Kiassen, McCluskey, Milgrom, Steblay, Andres, Wilson,
and Rudofsky report that interstitial nephritis could be
mediated by the immune system
Present — Growing knowledge of tubulointerstitial antigens,
nephritogenic T-cells, and fibrogenic processes
Table 3. Nephritogenic immune-response profile for
interstitial nephritis
Antigen- Immune-
recognition phase regulatory phase Effector phase
Antigens Suppressor and
contrasuppressor
T-cell networks
T-cell-dependent
antibody generation
Abrogation of In-situ formation
tolerance
Immune-response Nonspecific Immune-complex
genes suppression deposition
Immune activation IgE synthesis
Accessory cell Immune modulation
presentation of MHC
expression
Complement
Helper cell Mononuclear cells
activation and T-cells
differentiation
of effector T- Eosinophils/mast cells
cell events Histokines
Table 2. Patterns of human interstitial nephritis
Human phenotype
Murine
counterpart
I.
2.
3.
Mononuclear cells
Mononuclear cells
plus immune
complexes
Mononuclear cells
plus anti-TBM
antibodies
kdkd mice [10, ll1
NZBIW mice [12]
SJL mice [13, 14]
Numbers in brackets refer to references.
Eosinophils, neutrophils, and basophils can be present; rarely,
eosinophils overwhelmingly predominate. When infection is
responsible for acute interstitial nephritis, neutrophils typically
are present in large numbers. Cellular infiltrates in this acute
lesion are profuse throughout the cortical interstitium in asso-
ciation with interstitial edema, disruption of the tubular base-
ment membranes (TBM) and, in severe cases, dissolution of
normal interstitial architecture. Immunofluorescent studies gen-
erally are negative for antibodies and immune deposits [15, 16].
The second histologic pattern looks just like the first, except
that immunofluorescence reveals immune complexes along the
TBM that sometimes are associated with complement [17]. The
third pattern also resembles the first, but immunofluorescence
shows linear staining of the TBM, usually with IgG and com-
plement [18, 19]. This third form of interstitial injury is known
as anti-tubular basement membrane (anti-TBM) disease.
The acute and chronic forms of interstitial nephritis, at a
histologic level, seem to be a continuum along which an initial
inflammatory, cell-mediated response is subsequently over-
taken by destructive fibrogenesis. This transition to fibrogenesis
can occur quickly, and increased extracellular matrix is often
evident after only 7 days of interstitial inflammation. Cell-
mediated inflammatory events play an important role in the
development of the chronic interstitial lesion [20]. These cellu-
lar infiltrates provide important lymphokines, which modulate
the biogenesis of new extracellular matrix. The expansion of
this matrix in the setting of tubular atrophy and tubular disso-
lution presumably insulates damaged tissue from further attack
by antigen-dependent, cell-mediated events.
I believe that virtually all forms of human interstitial nephritis
probably have an immunologic basis, regardless of the inciting
event. Most information on the pathogenesis of interstitial
injury, however, comes from studies in experimental animals.
The nephritogenic immune response producing interstitial ne-
phritis can be arbitrarily divided into three general phases
(Table 3). The afferent or antigen-recognition phase begins with
the loss of tolerance to self-antigens and the genetically deter-
mined ability to respond to foreign antigens. The immune-
regulatory phase comprises protective processes that influence
the amplitude and qualitative nature of that immune response.
The third and final phase is the efferent or effector phase; it
includes the mechanisms directly responsible for producing
interstitial damage by antigen-specific T-cells, immune com-
plexes, or tissue-specific antibodies with subsequent fibrogen-
esis.
Antigen-recognition phase. Interstitial inflammation is fo-
cused towards target antigens in or of renal interstitial tissues.
Probably several families of endogenous parenchymal tubuloin-
terstitial antigens are nephritogenic in hosts that have lost their
immunologic tolerance to such moieties [21—24]. The antigen of
anti-TBM disease, for example, is called 3M-i [24]. Molecular
mimicry from infectious agents also can target immunologic
cross-reactions to homologous parenchymal structures in the
tubulointerstitium [25, 26]. Various drugs may act as a hapten-
bridge [27], binding to the tubulointerstitium and altering paren-
chymal structures, thus making them immunogenic. Other
drugs also can damage interstitial structures through toxic
mechanisms that produce nephritogenic neo-antigens [15].
Mammals with complex immune systems normally acquire a
tolerance for their own parenchymal tissues [28]. Such unre-
sponsiveness is vital to survival and probably results from one
of several mechanisms influencing the development and capa-
bility of the T- and B-cell repertoires. Because T-cells only
respond to antigen in the context of the major histocompatibil-
ity complex (MHC), a failure of endogenous or foreign antigens
to associate properly with MHC molecules on the surface of
epithelial, endothelial, or antigen-presenting accessory cells
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could constitute an ineffective stimulus for the immune system
(the determinant-selection theory) [29]. Maturing T-cells with
receptors for parenchymal antigens, alternatively, can be elim-
inated during ontogeny, and the immune system eventually will
fail to recognize relevant tissue antigens (the clonal-deletion
theory) [301. Finally, autoreactive T-cells, if present, may be
functionally impaired by suppressor T-lymphocytes that inhibit
the productive recognition of self-antigens (the peripheral-
suppression theory) [28, 31]. These regulatory processes are not
mutually exclusive, and they jointly might protect the paren-
chyma from immune injury.
When the limits of tolerance have been overcome or sub-
verted [32], helper T-cell recognition of nephritogenic ligands
can ensue unimpeded by self-protective restraints [31]. These
nephntogenic ligands probably activate T- and B-cell reper-
toires either in the peripheral immune system [13] or directly
within the tubulointerstitium. Tubular epithelium, for example,
can present self-antigens directly and might play an important
role in this activation process [33]. Successful engagement of
the immune system by local parenchymal cells probably is
regulated by autocrine and paracrine interactions that create the
optimal environment for self-recognition.
Which individuals of a species make a helper T-cell response
to a particular antigen is determined, in part, by the immune-
response genes carried in the major histocompatibility complex
[34, 35]. These genes are important in determining susceptibility
to autoimmune disease [36, 371. Immune-response genes exert
their influence by providing gene products that modulate or
influence two basic lymphocyte functions, those of intensity
and specificity [38], and those related to genetic restriction [13,
34]. Restriction refers to the fact that T-lymphocytes recognize
relevant antigens only when they are presented to the T-cells in
the context of certain MHC gene products and not in the
presence of others. The intensity of an immune response is
genetically determined not only by the presence of antigen-
reactive lymphocytes, but also by the relative balance among
helper, suppressive, and contrasuppressive influences [39, 40].
When nephritogenic helper T-cells are activated following an-
tigen recognition, a number of clones respond and the rest of
the nephritogenic immune response sequentially evolves from
this activated helper T-cell repertoire [41].
Immune-regulatory phase. Helper T-cells, responding to
tubulointerstitial antigens, induce the differentiation of nephri-
togenic effector T- and B-cells that can directly injure the
kidney. Interstitial nephritis is a relatively uncommon immune
response, probably because any activation of the nephritogenic
T- and B-cell repertoires is normally self-limited by specific
down-regulatory events [11, 32, 35]. These regulatory events
are controlled by either complementary interactions in the
immune repertoire [32], or by the immunologic visibility of the
target antigen [42, 43].
A major component of the immunoregulatory process is the
suppressor T-cell network. In some forms of interstitial nephri-
tis, the onset of disease correlates temporally with the func-
tional inactivation of regulatory suppressor T-cells by a distinct
subset of antigen-specific contrasuppressor T-lymphocytes
[40]. That is, the potential for autoimmune tubulointerstitial
damage is kept in check by these endogenous suppressor
T-cells, and such regulation is subverted by the expansion of
contrasuppression [44]. In other forms of interstitial injury, the
genetically determined presence of contrasuppression influ-
ences the selection of nephritogenic effector T-cells [45]. Not all
effector T-cells are capable of producing interstitial injury [41].
Those that are, however, may be developmentally preferred
and selected by the presence of contrasuppression [45].
Antigen-specific, cell-mediated responses require focused
recognition of the target ligand in the context of MHC mole-
cules, so the nephritogenic immune response also could be
modulated by changing the visibility of such MHC determinants
within the kidney. It has recently been shown, for example, that
antibodies (anti-TBM-Ab) from animals with interstitial nephri-
tis can down-regulate MHC class-Il expression on proximal
tubular epithelium secreting the antigen of anti-TBM disease
[43]. Because T-cells only recognize antigen in the context of
cell-surface MHC determinants, this antibody response,
amongst its many potential effects, could also diminish intersti-
tial inflammation by locally altering T-cell responsiveness.
The regulatory events surrounding the development of the
nephritogenic immune response therefore constitute an impor-
tant facet in the development of interstitial injury. The immune-
response genes carried by specific individuals probably are
important in determining the format of the immune response.
The competing actions of these regulatory phenomena ulti-
mately define the destructive capacity of various nephritogenic
processes.
Effector phase. Combined actions of immune-response
genes, the process of antigen-recognition, and the regulation of
differentiating immune repertoires provide a variety of potential
effector mechanisms that can directly injure the tubulointersti-
tium during interstitial nephritis.
The presence of primary immune deposits in interstitial
lesions is relatively uncommon. Presumably the host with the
proper susceptibility genes provides a B-cell response, either to
exogenous antigens discontinuously scattered along the tubular
basement membrane or to endogenous tubular antigens located
in an interrupted or linear configuration. Antibodies in the
tubulointerstitium probably bind as an in-situ process rather
than as the result of precipitation of circulating immune com-
plexes; immune complexes probably would have precipitated
first in the glomerulus. Antibodies to tubulointerstitial struc-
tures may directly produce inflammation by activating comple-
ment [46], inducing chemotaxis [47], invoking tubular injury by
direct cytotoxic effects on tubular cells [13], or by acting as an
informational bridge between antigen and mechanisms of anti-
body-dependent, cell-mediated cytotoxicity [48].
Occasionally the humoral immune response produces IgE
antibodies (Fig. 2), which are preferentially induced by selected
antigens derived from parasites, allergens, certain bacterial
products, or drug hapten-carrier molecules. The IgE response is
regulated by different sets of T-lymphocytes that secrete col-
laboratively interactive lymphokines, including several inter-
leukins, y-interferon, and two IgE-binding factors [49, 50].
These latter IgE-binding factors share a common structural
protein core that is modified by differential glycosylation during
the post-translational phase of their synthesis. In the presence
of selected antigens, some of these lymphokines are directly
involved in the induction of IgE-secreting B-cells, leading to the
synthesis of IgE antibody. The IgE antibody produced then can
directly bind to special receptors on tissue eosinophils, baso-
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Fig. 2. Factors that control IgE synthesis and lead to eosinophil and
mast-cell activation. B-cells that synthesize IgE are supported in their
development and biosynthetic function by antigen-presenting cell(APC) activation of TH2 cells providing IL-4 and IL-S. TH1 cells
expressing y-interferon can counteract the permissive effects of TH2
cells on B-cell (B) development. THR cells secrete IgE-potentiating or
-suppressive factors that, in combination with other lymphokines, can
modulate IgE production. IgE itself, as well as Fc receptors for IgE, can
feed back to modulate B-cell synthesis. IgE can bind to high-affinity
(FceRI) receptors on mast cells and low-affinity (FceRII) receptors on
eosinophils (Eo). The ability of mast cells and eosinophils to respond to
IgE also depends on the permissive effects of T-cell lymphokines. Mast
cells require IL-3 and IL-4, and eosinophils require IL-S. (Modified
from Ref. 49).
phils, and mast cells primed by other T-cell interleukins. A
coordinated hypersensitivity response can then ensue.
Complement proteins also have been observed to a varying
degree in interstitial lesions. Complement activation can be
seen in association with immune deposits [51] or with IgE
antibodies and interstitial eosinophils [52], as well as following
the passive transfer of anti-TBM-Ab [46]. Interestingly, com-
plement proteins also have been observed occasionally in
interstitial lesions when the humoral immune response does not
appear to be a component of the nephritogenic process. Anti-
body-independent complement activation may occur locally in
the kidney in the presence of ammonia. Triggering of the
alternative complement pathway by amidated C3 can produce
peritubular complement deposition and the release of other
inflammatory mediators that may injure tubulointerstitium [53].
Cytotoxic T-cells also release various proteases that have some
structural homology with selected complement proteins [54]; it
therefore is tempting to speculate that, in some cases, the
Table 4. T-celI-associative recognition molecules
T-cell
MHC Restriction Lymphocyte/phenotype Functiona
Class I
Human: A/B regions
CD8 Th,Td,Ts,Tc
Mouse: K/D regions
Class II
Human: D region
CD4 Th,Ts,Td,Tc
Mouse: AlE region
apparent recognition of traditional complement activation might
really be the result of cytotoxic T-cell damage.
Many forms of interstitial nephritis are not accompanied by
IL-5 complement deposition in interstitial lesions, however. Animals
deficient in C4 and CS complement components also can
develop interstitial lesions [14, 551. Complement activation thus
might be sufficient to produce interstitial injury, but it is not
always necessary. The activation of complement in the pres-
ence of inflammatory lesions also could be part of the healing
phase that leads to the dissolution of the humoral immune
response [56].
The hallmark of active interstitial inflammation is the pres-
ence of mononuclear cells [57, 58]. As I mentioned earlier,
these mononuclear cells usually are a mixture of T-lymphoyctes
and macrophages. Occasionally some B-cells also are observed
in these lesions. Both CD4 and CD8 T-lymphocyte subpop-
ulations usually are present in active interstitial infiltrates.
Because it is difficult to infer function from phenotype (Table 4),
a changing ratio or preferential emergence of one phenotype
over the other is not particularly informative.
Experimental work, for example, has shown that nephrito-
genic helper T-cells producing interstitial nephritis are usually
CD4- and class lI-restricted 159]. The effector cells can either
be CD4 or CD8 [41, 43], but they are usually CD8 and class
I-restricted [10, 40, 41]. In addition, these lesions can contain
various subpopulations of suppressor cells that are either CD4 +
or CD8. Effector T-cells produce injury by two general
mechanisms. They can induce delayed-type hypersensitivity
responses with the release of inflammatory lymphokines and
mediators [41, 60, 61], or they can produce cell-mediated
cytotoxicity [13, 41] against a target by releasing proteases
called performs [54].
Eosinophils occasionally are demonstrable within a mixed
cellular infiltrate producing interstitial injury [62]. Eosinophils
are drawn into such infiltrates by eosinophil chemotactic factor
released by mast cells, and by local concentrations of IgE (Fig.
3). At one time it was believed that eosinophils were drawn into
the inflammatory process to control and attenuate the inflam-
matory effects of mast cell degranulation. It is now appreciated,
however, that eosinophils express low-affinity IgE receptors
and that mast cells express high-affinity IgE receptors [49].
Degranulation of both cell types can occur when local IgE is
cross-linked with its ligand. In the permissive environment of
T-cell lymphokines, eosinophils as well as mast cells release
0
ii,
/ N00
IL-3 IL-4 IL-5 gIFN
GE FIG IF
1
a Least prevalent T-cell function; , most prevalent T-cell
function; Th, helper; Td, delayed hypersensitivity; Ts, suppressor; Tc,
IgE-PF/IgE-SF cytotoxic cells.
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Fig. 3. Induction of hypersensitivity responses by IgE. igE crosslinked
to its ligand can bind to either high-affinity receptors on mast cells or to
low-affinity receptors on eosinophils. This process leads to degranula-
tion and the production of eosinophil chemotactic factor (ECF) by mast
cells. Degranulation induces the release of proteases, histamine, PAF
(platelet activating factor), leukotrienes, prostaglandins, and peroxi-
dases. Eosinophils also release major basic protein (MBP) and eosino-
philic cationic protein (ECP), which are cytotoxic. Degranulation and
the release of inflammatory mediators initiate local injury; Although
eosinophils to a large extent are attracted to inflammation by mast-cell
release of ECF, eosinophils are not necessarily neutralizing in their
presence and effect. Like the mast cell, they can directly contribute to
the inflammatory process that ensues.
proteases, leukotrienes, superoxides, and peroxidases [63, 64].
Eosinophils also provide major basic protein and eosinophil
cationic protein, which might have inflammatory actions of
their own [63].
Helper and effector T-cells also can release lymphokines that
modulate the growth and biosynthesis of extracellular matrix in
tubular epithelium and fibroblasts [20, 65]. This relationship
between the nephritogenic immune response and the produc-
tion of extracellular matrix leading to fibrogenesis is an impor-
tant link in the transition between acute and chronic injury [66].
The effects of T-cell lymphokines might be antigen-specific or
nonspecific and, in aggregate, could substantially modulate the
Table 5. Determinants of susceptibility to anti-TBM disease
1. Expression of the 3M-I target antigen
2. Abrogation of immunologic tolerance
3. Presence of immune-response genes regulating contrasuppression
4. Visibility of parenchymal MHC antigens
architectural remodeling observed during progressive intersti-
tial injury.
Determinants of susceptibility to anti-TBM disease
The young woman described in the case presentation has a
unique form of acute interstitial nephritis called anti-TBM
disease [15, 16, 24]. A great deal is known about the determi-
nants of susceptibility to anti-TBM disease from work in
experimental animals. Four important determinants are listed in
Table 5, and all of these closely map with the genotype of the
afflicted host.
The target antigen of anti-TBM disease is a glycoprotein
(3M-i) secreted by proximal tubular cells into the extracellular
matrix [67]. The glycoprotein attaches to the outer surface of
the TBM. Although immunofluorescent staining for anti-TBM-
Ab illustrates a linear deposition, the glycoprotein does not
seem to be a part of the structural fabric of the TBM proper.
Rather, this glycoprotein is applied to the outer edge of the
TBM and streams off attached to interstitial reticulum (68].
New research using cDNA cloning of 3M-I has demonstrated
four isoforms of this protein [691. Segments of this protein are
preserved among mice, rats, guinea pigs, and humans [13, 14,
24, 70—76]. Within a species, however, some polymorphism of
expression also occurs [70, 75]. Not all rats and humans, for
example, express this glycoprotein [75, 77]. Thus, the first
important determinant of susceptibility to anti-TBM disease is
that an individual must express 3M-i in order to focus the
nephritogenic immune response. I would estimate that more
than 95% of humans express this antigen, but precise figures are
not known.
Normal individuals who express the 3M-i antigen generally
do not develop anti-TBM disease because they are immunolog-
ically tolerant to this tubular moiety. Such tolerance is main-
tained, in part, by the presence of protective 3M-i-antigen-
specific suppressor T-cells [31], To activate the process of
antigen-recognition and effector B- and T-cell differentiation, an
individual must overcome tolerance to parenchymal self. This
tolerance can be broken by impairing normal surveillance
systems with immunosuppressive drugs [31], introducing a
foreign antigen that cross-reacts with a self structure [13, 211, or
by creating a neo-antigen, as in a drug reaction [27]. Humans
with anti-TBM disease also have developed interstitial injury
either spontaneously [16, 24], or in the renal transplantation
setting where a recipient not expressing 3M-i in the native,
damaged kidneys receives a graft expressing 3M-i [77]. For
someone to develop anti-TBM disease, therefore, a break in a
protective surveillance mechanism must occuf, or tolerance
must be bypassed by another process.
Anti-TBM-Ab from different species, including humans, are
directed to an immunodominant epitope on 3M-i [78]. Possess-
ing the nephritogenic 3M-i antigen and being able to mount an
autoimmune B-cell response, however, is not sufficient for the
expression of interstitial disease. The functional capacity of
cellular events is of major importance [75, 79—83]. Certain
IgE + Ligand
—ECF
1 1!
Proteases
Histamine
PAF MBP/ECP
Leukotrienes
Prostag Ia nd in s
Superoxides/H 0
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mouse and rat strains, for example, although possessing the
target antigen and making anti-TBM antibodies, do not develop
mononuclear cell infiltrates [61, 75]. Failure to produce inter-
stitial lesions in these circumstances is due to the lack of
important cell-mediated immune-response genes that map to
the class-I region of the MHC [13, 45]. Early in the anti-TBM
immune response, both CD4 and CD8 effector T-cells de-
velop in all mice [41]. But CD4 effector 1-cells preferentially
emerge in non-susceptible mice. These cells can recognize
tubular antigen. They are genetically restricted to class-Il MHC
determinants, however, and apparently do not recognize the
revelant tubular antigen locally within the kidney [43]. Mice
susceptible to anti-IBM disease, on the contrary, preferentially
select for the nephritogenic CD8 effector T-cell repertoire
[41], which is restricted by class-I MHC determinants [61].
Non-susceptible mice have such effector I-cells, but the expan-
sion of this cell-mediated network is inhibited by other regula-
tory I-cells that normally reside in the lymphoid system [41,
45]. These regulatory T-cells suppress the emergence of CD8
effector cells. Immune regulation of effector T-cell preference
thus critically determines susceptibility to the development of
anti-TBM disease. These suppressor T-cells, although protec-
tive in non-susceptible mice, are subverted by contrasuppressor
lymphocytes in susceptible mice [45]. The presence of these
contrasuppressor cells also is genetically restricted by class-I
determinants, and it is this process in susceptible mice that
allows for the development of interstitial injury.
Recent evidence now suggests that CD4 nephritogenic
T-cells can produce interstitial injury under highly controlled
experimental conditions in which MHC class-Il determinants
on tubular epithelial cells are up-regulated to improve T-cell
recognition of 3M-i [43]. Anti-tubular-membrane antibodies,
which bind to tubular epithelium, however, protectively down-
regulate their transcription of MHC class-Il determinants.
Control of MHC visibility serves as the final, important deter-
minant of susceptibility [42, 43]. In theory, CD4 nephritogenic
effector cells in non-susceptible animals eventually might rec-
ognize 3M-l antigen in the kidney over time, even though
visibility is low. The presence of anti-IBM-Ab greatly dimin-
ishes this prospect and preserves the non-susceptibility status
of this particular host.
Diagnosis of interstitial nephritis
Acute renal failure typically is recognized by an abrupt
decrease in renal function in an otherwise unremarkable patient
who has undergone surgery, has had an intervening illness, or
who was given a new medication (Table 6). On many occasions,
distinguishing among acute tubular necrosis, subtle glomerulo-
nephritis, or acute interstitial nephritis may be difficult without
a renal biopsy. Several clinical features can help distinguish
acute interstitial nephritis from other diagnoses (Table 7).
Factors in the patient's history, such as uveitis, Sjögren's
syndrome, systemic infection, sarcoidosis, or a drug reaction
sometimes suggest the possibility of interstitial injury. The
patient with drug-induced acute interstitial nephritis commonly
has systemic manifestations of an allergic process. For a drug to
produce an allergic reaction, there usually has been a previous
exposure [84], which might explain why many patients with
drug-induced interstitial nephritis develop the lesion quickly,
that is, in 3 to 5 days. This rapidity is consistent with an
Table 6. Causes of acute interstitial nephritis
Diagnostic group Common Uncommon
History of drug hypersensitivity or infection
Sudden onset (days to weeks)
Sometimes flank pain
Acute renal failure (FENa >1)
Kidney size normal or increased
Variable hypertension, fever, or eosinophilia
Urinalysis
Microscopic hematuria
Mild proteinuria (usually <1.5 g124 hr)
White blood cells or white blood cell casts
Occasionally eosinophils
Leprosy
Rickettsia
legionella
Syphilis
Leptospira
Toxoplasma
Brucella
Mycoplasma
Measles virus
Epstein-Barr virus
Antibiotics
Oxacillin
Nafcillin
Tetracycline
Diuretics
Thiazides
Furosemide
Triamterene
Ethacrynic acid
Phenytoin
Allopurinol
Cimetidine
Anti-TBM disease
SjOgren' s syndrome
TINU syndrome
anamnestic secondary immune response. If the patient has been
taking a new drug for a number of weeks, however, an
interstitial immune response can emerge as a primary process.
Skin rash is present in less than 50% of patients with drug-
induced interstitial injury: fever occurs in approximately 75%,
and eosinophiiia appears in 80%. The triad of rash, fever, and
eosinophilia, however, is present in less than one-third of
drug-induced cases [84] and is uncommon in individuals with
acute interstitial nephritis secondary to nonsteroidal antiinflam-
matory drugs [85]. Bilateral or, occasionally, unilateral lumbar
pain has been described, and probably is due to a distension of
the renal capsule following diffuse swelling of the kidney [86].
There do not seem to be good figures on the frequency of
elevated serum IgE antibodies in these patients. In theory, the
frequency should be the same as the frequency of finding
eosinophils in the interstitial lesions (Fig. 3). What information
is available, however, seems to suggest that the frequency is
somewhat lower, and that the ability to detect elevated serum
IgE might depend on whether the allergic/reaginic response is
principally local in the kidney, or systemic in nature. Urinalysis
reveals mild to moderate proteinuria with hematuria. Gross
hematuria occasionally has been reported, although the sedi-
ment in approximately 90% of patients shows only moderate
Systemic infection
Drug reaction
Immune or immune-
like inflammation
Diphtheria
Streptococci
Antibiotics
Methicillin
Penicillin
Ampicillin
Cephalosporins
Sulfonamides
Rifampin
Phenindione
Nonsteroidals
Sarcoidosis
Table 7. Clinical findings of acute interstitial nephritis
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amounts of red and white blood cells [84]. White blood cell
casts frequently are observed; red blood cell casts are so rare
that their presenpe should suggest an alternative diagnosis of
glomerular injury. The finding of eosinophils in the urine tends
to support the diagnosis of allergic interstitial nephritis. In
patients with interstitial nephritis from drug administration
(except nonsteroidal antiinflammatory drugs), eosinophiluria
can be observed in up to 86% of cases [87—89]. Less than 5% of
patients with interstitial nephritis from nonsteroidal antiinflam-
matory drugs, however, have eosinophiluria [85]. The demon-
stration of eosinophils in the urine can be best documented with
Hansel's stain (100% of urines containing eosinophils), as
opposed to a Wright's stain, in which eosinophils could only be
detected in 18% of urine samples from patients with interstitial
nephritis [881. The absence of eosiñophiluria, however, never
should be used to exclude the diagnosis of acute interstitial
nephritis. Eosinophils in the urine, furthermore, frequently can
be observed in the setting of acute prostatitis or rapidly pro-
gressive glomerulonephritis [88], so the finding must be consid-
ered in the context of the clinical setting, or correlated with the
results of kidney biopsy where appropriate.
The magnitude of proteinuria in acute interstitial injury can
vary considerably. Nephrotic-range proteinuria is uncommon
unless interstitial lesions are associated with minimal-change
glomerulonephritis following the use of nonsteroidal antiinflam-
matory drugs [85]. Most patients with acute interstitial injury
have a fractional excretion of sodium greater than 1% [84], and
they can be either oliguric or nonoliguric [87]. Specific renal
tubular abnormalities and electrolyte or acid-base disturbances
are not common in acute interstitial nephritis. These metabolic
complications, in general, are only observed in chronic inter-
stitial injury, where the lesion pursues an indolent course. In
acute interstitial nephritis, the metabolic problems are, in
essence, the general complications of acute renal failure. Ra-
diographic imaging procedures should be chosen to facilitate
the differential diagnosis of acute renal failure, as there are no
convincing techniques that strongly corroborate the presence of
acute interstitial nephritis.
Because the clinical history, physical findings, urinalysis, and
laboratory evaluation can lead to uncertain conclusions, a renal
biopsy may be needed in patients with acute renal failure who
lack the findings of prerenal azotemia, whose clinical picture
does not reflect acute tubular necrosis, and in whom obstructive
nephropathy has been excluded by previous evaluation. I use
three general criteria to decide when a biopsy is appropriate in
a patient suspected of having acute interstitial nephritis. First,
one must determine whether the clinical setting warrants a
tissue diagnosis to assess the pattern of the lesion or the extent
of its involvement. Second, the patient has to be stable enough
to undergo a renal biopsy, and have a general medical condition
adequate to tolerate the administration of immunosuppressive
drugs. Finally, the physician has to believe that the character of
the lesion, and the extent of involvement, will affect the
therapy. I believe renal biopsies generally are safe and provide
much valuable prognostic information.
Treatment of acute interstitial injury
Many cases of acute interstitial nephritis resolve when the
inciting factors are removed. The probability of good recovery,
however, depends on the duration of renal failure prior to its
Fig. 4. Alogrilhm for the treatment
(Reprinted from Ref. 103.)
discovery. The final serum creatinine level averages approxi-
mately 1 mg/dl in patients with acute renal failure who are
treated within the first 2 weeks, compared with 3 mgIdl in those
who are diagnosed and treated after 3 weeks of acute interstitial
injury [90]. The presence of scattered infiltrates in acute inter-
stitial nephritis also is associated with the return of normal renal
function, whereas diffuse involvement often results in persist-
ent functional impairment. Prolonged or unrecognized intersti-
tial damage usually leads to irreversible chronic interstitial
fibrosis. Figure 4 is a therapeutic algorithm we use in attempting
to limit tubulointerstitial destruction.
Antigen-nonspecific therapy. I believe that a limited course of
high-dose prednisone generally is prudent for biopsy-proven
acute interstitial injury in which renal failure has persisted for
more than one week, after removal of any inciting factors, or if
no inciting factors can be identified after a thorough search. I
must admit that the evidence for employing prednisone in this
disease comes only from ancedotal case reports and small,
uncontrolled, nonrandomized studies [87]. Corticosteroids
sometimes are useful in the tubulointerstitial nephritis-uveitis
(TINU) syndrome [91] and, in my experience, early in the
course of interstitial nephritis from sarcoidosis. Acute intersti-
tial nephritis typically precedes fibrogenesis by as short a time
as 7 to 14 days, so it is reasonable to anticipate that patients
with substantial interstitial scarring in their renal biopsies will
benefit less from steroid therapy. A general time frame there-
fore exists for the use of steroids in acute interstitial nephritis:
Are there potential causative factors which can be removed or treated?
4
Yes No
Proceed accordingly
Is renal function improving after several days?
Yes
Observe
No
Is there marked interstitial fibrosis
on renal biopsy?
+ 4
Yes No
Manage conservatively Are there antitubular basement
membrane antibodies?
Yes No
Consider adding prednisone (1 mg/kg/day), Treat with prednisone (1 mg/kg/day)
cyclophosphamide (2 mg/kg/day), and
plasmapheresis (10 treatments over
2 weeks) Is renal function Improving after
7 to 10 days?
Yes No
Observe Consider adding
cyclophosphamide
(2 mg/kg/day)
of acute interstitial nephritis.
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steroids can be useful usually after one week of rising serum
creatinine, but before several weeks of persistent renal failure.
Steroids should be discontinued if no meaningful response is
achieved after 3 to 4 weeks of therapy.
Other immunosuppressive drugs also may be beneficial in the
treatment of acute interstitial nephritis. The use of such drugs,
however, has only been evaluated in animal models, particu-
larly in experimental anti-TBM disease. Extrapolation to the
human condition obviously must be qualified by this limitation.
It is a limitation which, unfortunately, is not likely to be
changed in the near future. There just are not large enough
numbers of patients with homogeneous interstitial lesions who
can be entered into controlled trials. Cyclophosphamide is
extremely effective in experimental animals with anti-TBM
disease if it is administered early in the disease process and if a
reasonable dose is used [831. For example, very low doses in
rats can exacerbate the interstitial injury, presumably by selec-
tively impairing suppressor T-cells without affecting the nephri-
togenic effector T-cell process [83]. Cyclosporine A also is quite
beneficial in treating anti-TBM disease in experimental animals
[81, 92], and is effective when therapy is initiated after the
interstitial process is fully active. Neither cyclophosphamide
nor cyclosporine A diminished the titers of anti-TBM-Ab within
the time frame of these experiments. This finding is consistent
with these drugs' direct action on the nephritogenic T-cell
repertoire. These agents therefore might be effective therapies
in patients with progressive renal failure who are not respond-
ing to steroids and in whom the renal biopsy reveals little or no
fibrosis. I would add such drugs within 2 weeks of prednisone
therapy and stop them after 5 or 6 weeeks if renal function did
not improve. If improvement in glomerular filtration rate could
be demonstrated, I would continue the cyclophosphamide for
one or two months longer and taper the steroids. Within this
time frame, I do not believe that cyclophosphamide poses a
serious oncogenic threat, and it probably would impose only a
small chance of limiting fertility. Given that fertility is likely to
be decreased with chronic renal failure anyway, I tend to accept
these risks with appropriate consultation and guidance from the
patient. The effectiveness of cyclosphosphamide, cyclosporine,
and prednisone also might be enhanced by reducing the pa-
tient's dietary protein ingestion during the early course of
anti-TBM disease. At least in experimental animals, a 3%
protein diet stabilized histologic lesions and renal function
compared with animals maintained on a 27% protein diet, in
which the disease progressed [931. This protective effect was
most likely the result of nonspecific inhibition of T-cell func-
tion.
The most critical feature of immunosuppressive manage-
ment, of course, is knowing when to stop treatment. All these
potential interventions take several weeks to achieve maximal
effect. Within a modest period of time, therefore, it should be
possible to reach a rational decision to do no more. Lengthy
treatment in the setting of renal failure can lead to metabolic
and infectious complications, which often prove fatal. The
promising experience with renal transplantation over the past
decade provides a viable alternative to hopeless renal failure.
Antigen-specific experimental therapies. Experimental anti-
TBM disease has provided us an opportunity to study a number
of antigen-specific regulatory interventions in animals. Such
regulatory networks are suppressive and often antiidiotypic
[32]. Idiotypes are unique variable-region gene products that
appear within the T-cell receptor and in or near the antigen-
binding variable region of the antibody molecule. An individual
idiotype on one of the immunologic receptors typically exists in
very low concentrations in the peripheral lymphoid system.
When an immune response is stimulated by an appropriate
target antigen, the idiotype is incorporated into the differenti-
ating B- and T-cell repertoires. As the concentration of one of
these idiotypes increases, so does its ability to be recognized by
the immune system as a new antigenic determinant. The immu-
nologic response to this new, unique gene product on these
receptors is the complementary production of other antibodies
and T-cells that are idiotype-reactive. This new response is
antiidiotypic and is believed to serve a critical immunoregula-
tory role, in large part by suppressing the function of lympho-
cytes bearing their complementary specificity. This integrative
network provides a predictable mechanism for modulating
antibody and cellular responses to nephritogenic antigens.
Induced antiidiotypic immunity can effectively down-regulate
anti-TBM disease in experimental animals. Rabbit antibodies
produced against monoclonal anti-TBM-Ab [78] or anti-TBM-
Ab eluted from nephritic kidneys [94] on passive transfer will
effectively block the development of interstitial lesions. Some
of these antiidiotypic antibodies also can halt the progression of
interstitial injury after it is established in anti-TBM disease [78].
Our experience with using T-lymphoblasts to induce protective
antiidiotypic antibodies furthermore suggests that the induction
of this antiidiotypic immunity impairs both antigen recognition
and the development of antigen-receptor heterogeneity [95].
Immune regulation in anti-TBM disease also can be accom-
plished through the induction of suppressor T-cell networks.
Pretreatment with tubular antigen in incomplete Freund's adju-
vant preferentially induces suppressor T-cells that block the
induction of interstitial nephritis in rats when they are subse-
quently challenged with the same antigen in complete Freund's
adjuvant [96]. These suppressor T-cells are antigen-specific,
idiotype-positive, and genetically restricted by the MHC. The
mechanism of suppression seems to be the result of functional
inactivation given that effector cells are present, but function-
ally inert, in mixed-cell populations harvested from protected
animals [97]. The ideal regulatory system, however, would
combine active T-cell suppression with antigen-specific or
antiidiotypic recognition using either syngeneic or autologous
control systems to minimize alloreactivity. The process also
would have to be inducible without adjuvant if it were to be
applicable to humans. Taking advantage of protocols popular-
ized in hapten systems [98, 99], we have induced a disease-
protective suppressor-T-cell network in mice using complemen-
tary idiotypic specificities as the basis for modulation of
nephritogenic effector T-cells producing anti-TBM disease
[100]. Suppressor cells can be harvested from donor mice
primed with tubular antigen-derivatized syngeneic lympho-
cytes. These derivatized cells, when injected intravenously,
induce at least two subsets of suppressor lymphocytes. The first
suppressor cell in this network is a Ts-l suppressor lympho-
cyte, which is tubular-antigen binding and which expresses an
idiotype unique to the immune response producing anti-TBM
disease in mice. The Ts-l cells can inhibit the afferent induction
phase of the nephritogenic immune response; they also induce
Ts-2 cells, which are antiidiotypic suppressors. These Ts-2 cells
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act on the effector limb of the cell-mediated immune response
that produces interstitial injury. These nephritogenic effector
cells share the same idiotype as the Ts- I cells and therefore are
complementary to the Ts-2 specificity. These suppressive
events are mediated by soluble factors released by the suppres-
sor T-cell network [101]; we currently are attempting to bio-
chemically characterize these factors. Of great interest is that
protection by Ts-2 cells also can be induced in mice that already
have anti-TBM disease [1021. This therapeutic strategy there-
fore offers the real possibility of using the host's own immune
system to modulate ongoing renal injury.
Questions and answers
DR. JOHN T. HARRtNGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): You alluded to
the difficulties in interpreting the clinical information on the
treatment of interstitial nephritis. Several years ago, Galpin and
associates showed that steroid therapy reduced the time inter-
val before serum creatinine returned to baseline; in treated
patients the interval was approximately 9 days, versus 54 days
in untreated patients [871. Are there any similar papers that
provide additional clinical data to help us?
DR. NEILs0N: Actually I did refer to this in my discussion,
There is an additional bit of information that provides some
clinical correlation [901. One correlation is that more diffuse
lesions are less likely to improve than are focal lesions. The
other correlation is that patients with acute renal failure from
interstitial nephntis who are treated within 2 weeks of onset will
probably end up with creatinine levels near 1 mg/dl; whereas
patients who aren't treated until after 3 weeks of acute renal
failure tend to end up with creatinines around 3.0 mg/dl. These
observations seem to be a validation of common sense; the
longer one waits to make a diagnosis and start therapy, the less
likely one is to get a good result.
DR. JEROME P. KASSIRER (Associate Physician-in-Chief, De-
partment of Medicine, New England Medical Center, Boston):
Because there are so many causes of acute interstitial nephritis
and because cases appear sporadically, there is no opportunity
to study a homogenous group of cases. As a consequence, we
have to rely on experimental models of acute interstitial nephri-
tis to elucidate pathophysiologic and therapeutic aspects of the
disease. For this reason, the veridicality of the models becomes
critical. Do you consider the experimental models a true
reflection of the clinical syndrome?
DR. NEILSON: As you know, all experimental models tend to
be an approximation of reality. I think some of the current
mouse models provide a pretty good representation of his-
tologic phenotype. The investigation of human interstitial ne-
phritis, in most cases, however, has not been critically analyzed
with isolated antigens and immunologic reagents produced from
experimental work. We have been gathering needed reagents to
pursue an analysis of the disorder in humans. The patient I
described today had anti-TBM disease, and the experimental
models have some significant parallels. In particular, the target
antigen seems to be immunologically similar, and the paratypic
recognition by anti-TBM-Ab seems to be highly conserved. The
T-cell repertoire in human anti-TBM disease, however, has not
been formally compared with its experimental counterpart for
similarities. Some of the therapeutic studies to which I have
referred in my discussion also were evaluated in experimental
anti-TBM disease. Some of our unpublished work, furthermore,
indicates that such therapies may apply to other forms of
experimental interstitial injury. That is about as close as I am
willing to get to veridicality.
DR. MICHAEL MADAIO (Division of Nephrology, New En-
gland Medical Center): Please comment on the potential risks
and benefits of empiric cytoxan therapy in this group of
patients. Pedersen-Bjergaard et al reported the cumulative risk
of bladder cancer in patients with non-Hodgkin's lymphoma
previously treated with cytoxan to be 3.5% at 8 years and 10.7%
at 12 years [104]. Although their patients might not be compa-
rable to patients with interstitial nephritis, the recommendation
of caution against treatment for patients with diseases that have
a favorable prognosis or in which cytoxan therapy has not been
proven beneficial seems appropriate.
DR. NEILSON: In my own practice, I don't consider persistent
interstitial nephritis a particularly benign lesion, but I don't
start cyclophosphamide in every patient, either. Most of my
own experience with the drug has been in steroid-dependent
interstitial nephritis from sarcoidosis. When I do use it, it is
usually in short courses of up to 12 weeks. Every patient who is
exposed to alkylating agents is put at some risk. The risk of
medical problems associated with progressive renal failure,
however, is not negligible either. In a current trial of therapy for
lupus [1051, treating reasonable numbers of renal patients with
a limited course of cyclophosphamide, in the doses and time
course I use in interstitial nephritis, the risk of bladder cancer,
to date, seems negligible. The experimental literature on the use
of cyclophosphamide looks quite promising. There are good
theoretical grounds for why it should be effective. I only use
cyclophosphamide after careful discussion with the patient.
Usually I have done a biopsy to be sure that the damage is not
too far advanced or seemingly irreversible. I don't think the
drug should be used in hopeless cases. In the setting of
advanced histologic change, it is much better to save the
immunosuppressive risk for transplantation.
DR. ANDREW S. LEVEY (Division of Nephrology, New En-
gland Medical Center): The interstitial lesions that occur in
chronic interstitial nephritis are very similar to the lesions that
occur in chronic renal diseases in which the primary injury is in
the glomeruli or vessels. Do you have any comments about the
pathogenesis and the mechanisms of progression of interstitial
lesions in these diseases?
DR. NEILSON: No, not really. This subject has successfully
eluded experimental study. If I were to speculate, I would say
that in some cases the nephritogenic immune response that
produces glomerular injury just spills over into the interstitium
[106]. In other situations, there may be shared antigenic expres-
sion in both the glomerular tuft and the tubulointerstitium [107].
Finally, inflammation in the glomerular tuft might release cyto-
kines (histokines) into the tubular fluid which, in their passage,
subsequently might alter the biosynthesis of extracellular ma-
trix in the tubulointerstitium.
DR. AJAY SINGH (Clinical Fellow in Nephrology, New En-
gland Medical Center): Given the impressive results that your
group has obtained with the use of cyclosporine in the animal
model [81], what are the human data, if any, on its use in
interstitial nephritis, and under what circumstances would you
use it?
DR. NEILSON: I have not heard that anyone has used cyclo-
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sporine in the treatment of human interstitial nephritis. In the
right doses, I think that it might work. Ideally it should be used
early, but the conventional wisdom, with which I agree, is to
first withdraw inciting agents and then try prednisone. Only a
few patients with enough good kidney left, who aren't respond-
ing, might be candidates for a second drug. I suppose someday
someone will try it. Obviously I would prefer a controlled trial,
but I don't think one can be done in primary interstitial
nephritis. There simply aren't enough patients for such a study.
Hopefully, when cyclosporine is tried, it will be in cases that are
not too terribly advanced.
DR. KA55IRER: If we are about to biopsy a patient we think
has interstitial nephritis, how extensively should we study the
biopsy material immunologically? Is there any value to identi-
fying the varieties of immunologic patterns with respect to
therapy?
DR. NEILSON: No, not with respect to therapy, not at least at
the moment. The vast majority of patients with interstitial
nephritis do not have immune complexes or anti-TBM antibod-
ies. These latter cases are just interesting variations of the
nephritogenic immune response. When a biopsy is performed,
however, I would advocate a complete pathologic analysis for
purposes of classification. These studies would include immu-
nofluorescence and electron microscopy.
DR. KASSIRER: If you could identify the tubular basement
membrane variety, would you consider using plasmapheresis?
DR. NEILs0N: Plasmapheresis has been tried in several of
these cases in an informal way. The argument for using it is
analogous to the argument for using it to treat anti-GBM
disease. I am sympathetic to this argument. To my knowledge,
the results to date have been mixed.
DR. PAUL KURTIN (Chief, Division of Pediatric Nephrology,
New England Medical Center): Is it true that patients develop
nephritis after re-exposure to rifampin as opposed to during the
first use of the drug? If so, what does that tell us about the
mechanism of the disease?
DR. NEILs0N: I am not aware that patients with presumed
rifampin-induced interstitial nephritis only get it after re-expo-
sure. Most of the patients have been on high-dose, intermittent-
weekly schedules over a continuous time-frame. Several gen-
eralizations, however, can be made regarding the presentation
of interstitial nephritis in patients receiving prescription drugs.
If patients are given a drug to which they later have an
allergic/immunologic response, it usually takes several weeks
for that primary response to appear. In some cases the response
will seem idiosyncratic, but in reality something else probably is
going on, such as the presence of susceptibility genes whose
activation might alter tolerance to drug-bound parenchymal
tissue, or the introduction of an environmental polyclonal
mitogen, or the accumulation of a drug metabolite that alters
mechanisms of tolerogenic balance. Many of us also have seen
patients who develop interstitial nephritis within 3 to 5 days of
starting a drug. These individuals probably are having an
anamnestic response to a previous primary exposure, or to a
cross-reactive exposure.
DR. KuRTIN: A linear anti-tubular basement membrane im-
munofluorescent staining pattern has been reported in penicil-
lin-induced interstitial nephritis. Can that form be differentiated
from the more idiopathic type that you are describing?
DR. NEILs0N: Yes, possibly, but it would require additional
testing. One might stain the renal biopsy specimen with anti-
bodies to penicillin [108].
DR. MADAI0: How do you account for the lack of an
appropriate suppressor response in susceptible hosts who
clearly have the capacity to generate one?
DR. NEILs0N: Some hosts have the potential for down-
regulating this nephritogenic anti-TBM immune response, but
their capacity is probably impaired. We have shown this
experimentally [109]. Animals with anti-TBM disease coordi-
nately develop a nonspecific suppression that appears after the
primary anti-TBM response. This nonspecific suppression
blocks the subsequent development of an appropriate regula-
tory event, particularly the evolution of anti-idiotypic immu-
nity. If this nonspecific suppression is removed, the primary
anti-TBM response can be attenuated.
DR. MADAI0: So a defect in these experimental animals is too
much nonspecific suppression?
DR. NEILs0N: Yes, that might be part of it.
DR. HARRINGTON: The case report ends with the patient
starting a course of immunosuppression. Can you tell us what
treatment she received and what the outcome was?
DR. NEILs0N: This woman did not respond to steroid therapy
and developed renal failure.
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